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ith Primary Percutaneous Coronary Intervention
enon Huczek, MD,* Janusz Kochman, MD,* Krzysztof J. Filipiak, MD, PHD,*
rzegorz J. Horszczaruk, MD,* Marcin Grabowski, MD,*† Radoslaw Piatkowski, MD,*
oanna Wilczynska, MD, PHD,* Andrzej Zielinski, MD,* Bernhard Meier, MD, FACC, FESC,‡
rzegorz Opolski, MD, PHD, FESC*
arsaw, Poland; and Bern, Switzerland
OBJECTIVES We sought to determine the prognostic value of mean platelet volume (MPV) for
angiographic reperfusion and six-month mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) treated with primary percutaneous coronary
intervention (PCI).
BACKGROUND Mean platelet volume is predictive of unfavorable outcome among survivors of STEMI when
measured after the index event. No data are available for the value of admission MPV in
patients with STEMI treated with primary PCI.
METHODS Blood samples for MPV estimation, obtained on admission in 398 consecutive patients presenting
with STEMI, were measured before primary PCI. Follow-up up to six months was performed.
RESULTS No-reflow was significantly more frequent in patients with high MPV (10.3 fl) compared
with those with low MPV (10.3 fl) (21.2% vs. 5.5%, p 0.0001). The MPV was correlated
strongly with corrected Thrombolysis In Myocardial Infarction frame count (CTFC) (r 
0.698, p 0.0001). Kaplan-Meier survival analysis showed six-month mortality rate of 12.1%
in patients with high MPV versus 5.1% in low MPV group (log rank  6.235, p  0.0125).
After adjusting for baseline characteristics, high MPV remained a strong independent
predictor of no-reflow (odds ratio [OR] 4.7, 95% confidence interval [CI] 2.3 to 9.9, p 
0.0001), CTFC 40 (OR 10.1, 95% CI 5.7 to 18.1, p  0.0001), and mortality (OR 3.2,
95% CI 1.1 to 9.3, p  0.0084). Abciximab administration resulted in significant mortality
reduction only in patients with high MPV values (OR 0.02, 95% CI 0.01 to 0.48, p 
0.0165).
CONCLUSIONS Mean platelet volume is a strong, independent predictor of impaired angiographic reperfusion
and six-month mortality in STEMI treated with primary PCI. Apart from prognostic value,
admission MPV may also carry further practical, therapeutic implications. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.065Cardiol 2005;46:284–90) © 2005 by the American College of Cardiology Foundation
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tlatelets play an important role in pathogenesis of acute
oronary syndromes. It has been shown that platelet size,
easured as mean platelet volume (MPV), correlates with
heir reactivity (1). Mean platelet volume is positively
ssociated with indicators of platelet activity including
xpression of glycoprotein Ib and glycoprotein IIb/IIIa
eceptors (2–6). Higher values of MPV characterize pa-
ients with myocardial infarction and unstable angina as
ompared to those with stable angina or noncardiac chest
ain, and elevated MPV has been recognized as an inde-
endent risk factor for myocardial infarction and stroke
7–10). An elevated MPV is associated with poor clinical
utcome among survivors of myocardial infarction (11,12).
ately, it has also been proved that there is a positive
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005, accepted March 29, 2005.elationship between MPV and the severity of acute isch-
mic cerebrovascular events (13).
To our knowledge, there are no reports on the predictive
alue of MPV in the era of primary percutaneous coronary
ntervention (PCI), which is currently the treatment of
hoice in acute ST-segment elevation myocardial infarction
STEMI). In our study we sought to determine whether
PV, measured on admission, can be used in determining
he risk of impaired reperfusion and six-month mortality in
TEMI patients treated with primary PCI.
ETHODS
atient population. Three hundred and ninety-eight con-
ecutive patients admitted with diagnosis of STEMI, within
2 h from the onset of symptoms, were primarily enrolled in
he study. Patients with cardiogenic shock within 24 h were
lso included; STEMI was defined as typical chest pain
asting for 30 min, with ST-segment elevation 1 mm in
wo consecutive precordial or inferior leads. In seven pa-
ients with no significant stenosis of the culprit lesion
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July 19, 2005:284–90 Prognostic Significance of Mean Platelet Volume50%) and in three patients with left main disease in
ngiography requiring urgent surgical intervention, primary
CI was not performed, and they were excluded from
urther analysis. Finally, the population of the study con-
isted of 388 patients (72.2% men, mean age 60  11.3
ears). Informed consent was obtained from all participating
atients. Permission for the study was obtained by the local
thics committee.
aboratory methods. In all cases, venous peripheral blood
amples for the MPV measurement were drawn on admis-
ion. Blood samples were taken into standardized tubes
ontaining dipotassium ethylenedinitro tetraacetic acid
EDTA) and stored in room temperature. All measure-
ents were performed 30 min after blood collection on
DVIA 120 Haematology System (Bayer Diagnostics,
arrytown, New York), with time to result approximately 5
in. The assessment of MPV was made without clopi-
ogrel, heparin, or abciximab on board.
ngiographic analysis. In each case, coronary angiography
as performed in standard projections for different coronary
rteries (INNOVA 2000, General Electric Company, Fair-
eld, Connecticut). Digital angiograms were than analyzed
y three independent, experienced interventional cardiolo-
ists, blinded to MPV results. All angiograms were assessed
ith a respect to Thrombolysis In Myocardial Infarction
TIMI) flow scale in infarct-related artery (IRA) at baseline
nd after primary PCI. In order to assess coronary blood
ow as a continuous variable, the corrected TIMI frame
ount (CTFC) was determined on final angiogram, as
escribed previously (14). Frame counts in vein graft culprit
essels were corrected by a factor of 1.6 to account for their
xtra length (15). No-reflow was defined as TIMI flow
rade 3 on the final angiogram, in spite of residual
tenosis 50%; absence of significant dissection; visible
hrombus; or prolonged spasm in IRA. Additionally, CTFC
40 was used to identify patients with impaired reperfu-
ion, as opposed to those with a CTFC 40 (14).
djunctive pharmacotherapy. All patients received 325
g acetylsalicylic acid before intervention and unfractioned
eparin during PCI on routine basis. Clopidogrel was given
300 mg loading dose, and subsequently 75 mg daily) for the
eriod of four weeks if stent implantation was performed.
Abbreviations and Acronyms
CI  confidence interval
CTFC  corrected TIMI frame count
EDTA  ethylenedinitro tetraacetic acid
IRA  infarct-related artery
OR  odds ratio
MPV  mean platelet volume
PCI  percutaneous coronary intervention
ROC  receiver-operating characteristic
STEMI  ST-segment elevation myocardial infarction
TnI  troponin Ihe glycoprotein IIb/IIIa inhibitors (abciximab) were ad- ainistered during PCI, at the discretion of the operator, as
0.25 mg/kg bolus and a 0.125 g/kg/min 12-h infusion.
tudy end points. The angiographic end point of the study
as the occurrence of no-reflow or CTFC40. The clinical
nd point was all-cause mortality at six months.
tatistical analysis. Patients were divided into tertiles
ased on MPV values estimated on admission. Continuous
ata are presented as means  SD. Differences in contin-
ous variables between groups were determined by t test or
ann-Whitney test, for variables with or without normal
istribution, respectively. To test the normal distribution,
he Kolmogorov-Smirnov test was used. For all continuous
ariables apart from hematocrit values, the test rejected
ormality. Categorical variables were summarized as per-
entages and compared with the chi-square test. The
pearman correlation coefficient was computed to examine
he association between two continuous variables. Survival
urves were constructed by the Kaplan-Meier method, and
ifferences in survival were assessed using the log-rank test.
he impact of MPV value on no-reflow phenomenon,
TFC 40, and mortality were evaluated using multivar-
ate logistic regression model. Stepwise selection procedure
ith 0.1 level for staying in the model was used to select
mportant predictors. The final models were evaluated by
sing a concordance (C) index. Positive troponin I (TnI) on
dmission was defined as any value above upper range (0.1
g/ml; Dimension, Dade Behring, Newark, Delaware). A p
alue (two-tailed) 0.05 was considered statistically signif-
cant and confidence intervals (CI) were 95%. All analyses
ere performed using 8.02 Version SAS statistical software
SAS Institute Inc., Cary, North Carolina).
ESULTS
aseline characteristics. No-reflow phenomenon was ob-
erved in 42 (10.8%) and CTFC 40 in 91 patients
23.5%). At six-month follow-up, 29 patients had died
7.5%). After the determination of baseline MPV values,
he study population was divided into tertiles (first tertile:
9.7 fl [n  130]; second tertile: 9.7 to 10.2 fl [n  126];
hird tertile: 10.3 fl [n  132]). A high MPV (n  132)
as defined as a value in the third tertile (10.3 fl), and a
ow MPV (n 256) was defined as a value in the lower two
ertiles (10.3 fl).
Demographic, clinical, and procedural characteristics in
ndividual groups are listed in Table 1. Patients with high
PV values were older, had also significantly longer mean
ime to reperfusion, and were more likely to have hyperten-
ion as compared with patients with low MPV (Table 1).
orrelation of MPV with other biomarkers. There was a
eak, although significant, negative correlation between
PV and platelet count (r  0.211, p  0.0001). Slight,
ut significant, positive correlation was also observed be-
ween MPV and leukocyte count (r  0.116, p  0.002).
latelet and leukocyte counts were not significantly associ-
ted with no-reflow, CTFC 40, or six-month mortality.
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Prognostic Significance of Mean Platelet Volume July 19, 2005:284–90e did not observe any significant correlation between
PV and other markers measured on admission (Table 2).
PV and angiographic reperfusion. The mean admission
PV was higher in the 42 patients with no-reflow on
ost-PCI angiogram (10.8  0.95 fl) compared with those
ithout no-reflow (9.9 0.85 fl, p 0.0001). Patients with
igh MPV had almost a five-fold higher risk of developing
o-reflow as compared to those with low MPV (21.2% vs.
.5%, p  0.0001). After adjusting for baseline character-
stics, high MPV remained a strong independent predictor
f no-reflow (odds ratio [OR]  4.7, 95% CI 2.3 to 9.9, p
0.0001) (Table 3). The cutoff value for the prediction of
o-reflow was 10.3 fl, as identified by receiver operating
haracteristics (ROC). The area under the ROC curve with
PV used to detect no-reflow was 0.76 (95% CI 0.72 to
.80). An MPV value of 10.3 had a sensitivity of 61.9%
95% CI 45.6% to 76.4%) and specificity of 74.3% (95% CI
9.3% to 78.8%) (Fig. 1)
Apart from MPV, in our data set, presence of multivessel
isease on pre-PCI angiogram (OR  3.5, 95% CI 1.7 to
.1, p  0.0007) and admission positive TnI (OR  4.8,
5% CI 1.6 to 14.3, p  0.004) were also independent
able 1. Baseline Characteristics According to Mean
latelet Volume
MPV Low
(n  256)
MPV High
(n  132) p Value
ale gender, % 71.9 72.7 0.859
ge, yrs 59.2  11.2 61.5  11.4 0.044
ime to reperfusion, h 4.7  3.6 6.1  4.6 0.002
eart rate, beats/min 76.7  16 79.1  17.3 0.122
BP, mm Hg 130.2  21.5 127.5  16.1 0.785
ystemic hypertension, % 58.2 71.2 0.012
iabetes mellitus, % 14.8 19.7 0.222
ctive smokers, % 57.8 50.0 0.143
ypercholesterolemia, % 43.8 38.6 0.334
rior MI, % 22.7 15.2 0.081
rior aspirin use, % 32.0 30.3 0.728
nterior wall MI, % 45.3 40.9 0.408
illip class, %
I 75.8 75.8 0.996
II 14.5 12.1 0.526
III 3.1 3.0 0.959
IV 6.6 9.1 0.385
RA, %
RCA 39.5 48.5 0.088
LCx 14.5 9.8 0.200
LAD 46.1 41.7 0.406
Vein graft 0.8 0.8 0.980
ultivessel disease, % 22.7 22.7 0.987
aseline TIMI flow
grade 0/1, %
80.9 83.3 0.550
tent utilization, % 84.8 79.5 0.195
bciximab
administration, %
50.0 56.1 0.258
ata are presented as the mean value  SD (p values for Mann-Whitney test) or
ercentage of patients (p values for chi-square test).
Aspirin  acetylsalicylic acid; IRA  infarct-related artery; LAD  left anterior
escending artery; LCx  left circumflex artery; MI  myocardial infarction; MPV
mean platelet volume; RCA  right coronary artery; SBP  systolic blood
ressure; TIMI  Thrombolysis In Myocardial Infarction.redictors of no-reflow. However, MPV maintained an Tndependent contribution to risk assessment of no-reflow,
egardless of TnI status on admission. High admission
PV was associated with significantly higher risk of devel-
ping no-reflow in patients with positive (p  0.0001) as
ell as negative TnI (p  0.0027) (Fig. 2).
Patients with high MPV had significantly higher mean
TFC than those with low MPV (48.4  23.5 vs. 30.3 
6.7, p  0.0001); MPV determined at the time of
dmission was correlated strongly with CTFC (r 0.698; p
0.0001). The higher the MPV value, the greater the
umber of cine frames needed to reach the distal part of the
RA after primary PCI (Fig. 3). High MPV on admission
as an independent predictor of impaired reperfusion de-
ned as CTFC 40 in univariate as well as multivariate
nalysis (Table 3).
To evaluate the prognostic power of multivariate models,
e compared two models: before and after incorporation of
PV. The C-index for no-reflow and CTFC 40 models
efore incorporation of MPV were 0.71 and 0.65, respec-
ively. After incorporation of MPV, the C-index values
ncreased to 0.78 and 0.82, respectively.
PV and long-term mortality. The mean MPV was
ignificantly higher in the 29 patients who died (10.40 
.85 fl) as compared with the 359 survivors (9.96  0.90 fl,
 0.0134). Figure 4 shows the Kaplan-Meier curves for
ix-month all-cause mortality in patients with low MPV
ersus those with high MPV. The all-cause mortality rate at
ix-month follow-up was significantly higher in patients
ith high MPV values as compared to those with low MPV
12.1% vs. 5.1%, p  0.0125). After adjusting for baseline
haracteristics, high MPV remained an independent pre-
ictor of six-month mortality (Table 3). The performance of
ultivariate model after incorporation of MPV showed
mprovement with the C-index increase from 0.82 to 0.86.
Moreover, the prognostic association between MPV and
ix-month mortality was even stronger in patients with
TEMI complicated with cardiogenic shock on admission.
ardiogenic shock cases were well balanced between low
PV (6.6%) compared with the high MPV group (9.1%, p
0.385). Eight of 12 patients with high MPV died in
ardiogenic shock (66.7%) as compared to only 3 of 17 with
ow MPV (17.7%, p  0.0074). Using logistic regression,
igh MPV appeared to be a strong and independent
redictor of mortality in cardiogenic shock (OR  9.3, 95%
I, 1.7 to 52.7, p  0.011).
able 2. Correlation Between Mean Platelet Volume and Other
aboratory Measurements
r p Value
latelet count 0.211 0.0001
eukocyte count 0.116 0.002
emoglobin 0.013 0.766
ematocrit 0.029 0.575
reatinine 0.015 0.766
roponin I 0.048 0.346
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July 19, 2005:284–90 Prognostic Significance of Mean Platelet VolumePV and abciximab use. Abciximab was administered in
02 patients (52.1%) at the discretion of the operator—in
linically assessed higher risk patients. Therefore, older age
mean age, 60.9  11.3 years vs. 59  11.2 years, p 
.092), longer time to reperfusion (mean time, 6.4  4.4 h
s. 3.8  2.9 h, p  0.0001), diabetes (22.8% vs. 9.7%, p 
.0005), hypertension (66.8% vs. 58.1%, p 0.074), history
f myocardial infarction (27.7% vs. 11.7%, p  0.0001),
nterior wall STEMI (55.9% vs. 30.6%, p  0.0001), heart
ailure on admission (Killip class 1, 35.2% vs. 12.4%, p 
.0001), and no-reflow (17.8% vs. 3.2%, p  0.0001) were
ore frequent among abciximab-treated patients as com-
ared with abciximab-untreated patients. Otherwise, both
roups were well balanced.
Six-month mortality rates in abciximab-treated patients
ere as follows: 8.6% in MPV low group and 10.8% in
PV high group. In abciximab-untreated patients, the
linical end point occurred in 1.6%, and 13.8%, respectively.
fter adjusting for baseline characteristics and occurrence of
o-reflow phenomenon, it appeared that abciximab admin-
stration resulted in significant mortality reduction only in
igure 1. The receiver-operating characteristic (ROC) curve for mean
Table 3. Prognostic Significance of Mean Plat
Unadjusted Odds Ratio
(95% CI)
No-reflow 4.7 (2.4–9.2)
CTFC 40 8.6 (5.1–14.6)
Six-month mortality 2.6 (1.2–5.5)
*Adjusted for age, gender, time to reperfusion, heart rate,
smoking, previous myocardial infarction (MI), anterior wall
disease, baseline Thrombolysis In Myocardial Infarction (TIM
laboratory values.
CI  confidence interval; CTFC  corrected TIMI framlatelet volume (MPV) for predicting angiographic no-reflow. The area
nder the ROC curve  0.76 (95% confidence interval 0.72 to 0.80).
F
tatients with high MPV values (OR  0.02, 95% CI 0.01
o 0.48, p  0.0165). Based on stepwise selection in
ultivariate logistic regression model for predicting mortal-
ty in this study, abciximab did not influence significantly
he six-month mortality neither in the low MPV subgroup,
or in all patients.
ISCUSSION
redictive value of MPV for no-reflow, CTFC, and
ix-month mortality. Failure to achieve TIMI flow grade 3
fter successful opening of the artery without angiographic
vidence of mechanical obstruction, observed in 5% to 20%
f patients treated with primary PCI and defined as no-
eflow phenomenon, is associated with more extensive
yocardial necrosis, worse segmental and global contractil-
ty of the left ventricle, malignant arrhythmias, and in-
reased mortality (16–18). Pathophysiology of no-reflow is
elieved to be multifactorial (19,20). Higher (slower)
TFC values after reperfusion therapy have also been found
o be associated with poor clinical outcome (21). In the
resent study, we demonstrated that no-reflow as well as
alculated CTFC 40 occur significantly more frequently
n patients with higher baseline values of MPV. Moreover,
olume
Value
Adjusted* Odds Ratio
(95% CI) p Value
0.001 4.7 (2.3–9.9) 0.0001
0.0001 10.1 (5.7–18.1) 0.0001
0.015 3.2 (1.1–9.3) 0.0084
lic blood pressure, hypertension, diabetes, hyperlipidemia,
ior aspirin use, Killip 2, infarct-related artery, multivessel
w grade 0/1, stent utilization, positive troponin I, and other
nt.elet V
p


systo
MI, pr
I) floigure 2. Association of mean platelet volume (MPV) in conjunction with
roponin I, with the frequency of no-reflow phenomenon.
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Prognostic Significance of Mean Platelet Volume July 19, 2005:284–90PV correlated with coronary blood flow expressed as
ontinuous variable (CTFC), which further strengthens the
ndings of this study. We assume that the presence of
arger, more reactive platelets or platelet aggregates may be
ssociated with intravascular plugging on both epicardial
nd tissue level of the IRA, thus resulting in no-reflow and
lower CTFC after primary PCI. Higher MPV may corre-
pond with the increased number of both platelet-leukocyte
nd platelet-platelet aggregates (22). Correlations be-
ween MPV and platelet count and MPV and leukocyte
ount observed in the present study might support this
ypothesis.
Several clinical and angiographic predictors of abnormal
eperfusion have been recently identified, although simple,
reprocedural biochemical markers are still searched for
23–25). Results from the present study support the idea
hat platelets play an important role in the pathophysiology
f no-reflow (20) and suggest that MPV may be considered
s a useful, independent, hematological marker allowing for
arly and easy identification of patients who are at a higher
isk of impaired reperfusion after primary PCI.
We also showed that measuring of MPV helps to select a
ubgroup of patients (MPV 10.3 fl) with significantly
igher mortality in six-month follow-up. Martin et al. (11)
roved previously that greater MPV, when measured six
onths after myocardial infarction, is associated with in-
reased risk of death and reinfarction in two-year follow-up.
owever, differently from the study mentioned above, we
easured MPV directly on admission. Although MPV was
orrelated with age, hypertension, and longer time to
eperfusion, it provided prognostic information that was
igure 3. Correlation between admission mean platelet volume (MPV)
nd corrected TIMI frame count (CTFC) assessed on final angiogram.ndependent of these variables. Our findings support and
p
hxtend the data from Pabon et al. (12), who found positive
orrelation between admission MPV and the in-hospital
ncidence of major acute coronary events.
PV status and potential benefit from abciximab admin-
stration. Administration of abciximab during primary PCI
esulted in significant reduction of six-month mortality in
atients with high MPV values. Interestingly, four large
linical trials in the setting of primary PCI failed to show a
ignificant mortality reduction with glycoprotein IIb/IIIa
nhibitor administration when compared to placebo, and
ne analysis from a recently published registry showed an
ven higher rate of cardiovascular events with glycoprotein
Ib/IIIa blockade (26,27). Thus, the method for better
election of patients who benefit from glycoprotein IIb/IIIa
nhibitor use is needed.
The results of the present study suggest that patients with
igh MPV on admission represent the group with higher
isk for thrombosis. To that end, the higher the risk for
hrombosis, the greater the benefit from abciximab admin-
stration. Apart from that, there is another possible expla-
ation for major abciximab benefits in patients with high
PV. In this paper we concentrated on platelet-mediated
ffects; however, it is known that phospholipid constituents
f the platelet membrane as well as platelet granules,
icroparticles, and other receptors appear to be increased
mong patients who have greater MPV (2–5). As such, the
otential mechanisms for heightened adverse events among
atients with larger platelets may be also related to increased
nflammatory triggers, not evaluated precisely in this study.
herefore, the abciximab benefits would be also greater in
his situation. It has been shown that heterotypic monocyte-
igure 4. Kaplan-Meier curves for all-cause mortality according to mean
latelet volume (MPV). The six-month all-cause mortality was 12.1% in
igh MPV versus 5.1% in low MPV.
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July 19, 2005:284–90 Prognostic Significance of Mean Platelet Volumelatelet aggregates are a target for abciximab, which sup-
resses monocyte tissue factor because of a reduction of
onocyte-platelet cross talk (28,29).
tudy limitations. There are several limitations of this
tudy. Previous studies have reported that MPV increases in
time-dependent manner when EDTA is used as antico-
gulant (30). However, a recently published study proved
hat when the measurement is performed within 2 h after
enipuncture, the anticoagulation with EDTA accounts for
ess than 0.5 fl increase in MPV (9). It is alleged that platelet
welling may be associated with different amounts of EDTA
n sample tubes (13). To minimize the effect of EDTA on
latelet size in the present study, standardized sample tubes
ere used, and all samples were processed early (at 30 min)
fter blood collection.
We could not exclude the presence of heterotypic platelet
ggregates in the high MPV group. We may assume—on
he basis of correlations between MPV and other laboratory
easurements—that such aggregates could be present (Ta-
le 2). However, such phenomenon would only be deter-
ined by flow cytometry, the method that is currently
ostly, time-consuming, and needs specialized equipment
21). Therefore, MPV still remains an easy, useful tool for
ndirect monitoring platelet activity in different situations
31,32).
Adjustment for mortality according to abciximab treat-
ent should be treated with caution because of the small
ample size. Especially in the high MPV arm, larger cohort
f patients would be required for a more meaningful
nalysis. Thus, our data concerning the potential MPV-
uided approach to the selection of patients that may benefit
rom abciximab use in acute myocardial infarction treated
ith primary PCI must be evaluated in larger-scale, ran-
omized trials.
An important practical limitation to the current data
eals with the availability of the MPV in the setting of PCI
or STEMI, when with a rapid door-to-balloon time this
nformation may not be available. However, if the strong
rognostic value of MPV is confirmed, the different types of
utomatic, rapid platelet function analyzers may resolve this
roblem in the future.
onclusions. Admission MPV is a strong and indepen-
ent predictor of impaired reperfusion and mortality in
TEMI treated with primary PCI. Apart from prognostic
alue, measuring of MPV may also carry further practical,
herapeutic implications.
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